Table 1.
Patient and tumor characteristics at baseline
| Tamoxifen dose (mg/day) | |||
|---|---|---|---|
| 1 mg (n = 39) | 5 mg (n = 40) | 20 mg (n = 37) | |
| Serum samples, (n) | 39 | 40 | 36a |
| Age (years)b | 62 (50, 70) | 62 (51, 71) | 58 (51, 65) |
| Body mass index (kg/m2)b | 25.5 (23.9, 29.1) | 25.7 (22.3, 30.5) | 26.0 (22.4, 28.3) |
| Pre/peri/postmenopausal (n) | 9/1/29 | 10/1/29 | 8/1/28 |
| Surgical specimen available (n) | 25 | 19 | 19 |
| Tumor size (mm) | 21 (17, 25) | 18 (15,26) | 17 (14, 21) |
| Menopause related symptoms at baselinec | |||
| Sweating, yes/no/missing | 12/18/9 | 6/15/19 | 11/14/12 |
| Night sweating, yes/no/missing | 15/15/9 | 7/17/16 | 8/20/9 |
| Hot flashes, yes/no/missing | 15/17/7 | 7/17/16 | 7/20/10 |
aSerum sample was not available from one patient in the 20 mg dosing group
bValues are presented as medians with lower and upper quartiles (Q1, Q3)
cMissing data; data not filled in the Menopause-Specific Quality of Life questionnaire by the patients